Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Announces Results of 2026 Annual Meeting of Shareholders
Summary
Regeneron Pharmaceuticals, Inc. reported the outcomes of its 2026 Annual Meeting of Shareholders held on June 12, 2026. Shareholders elected five new Class II directors and ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. An advisory vote on the compensation of the company's named executive officers was also approved. These decisions reflect the shareholders' confidence in the company's leadership and governance practices.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement